Search

Search Results

• 

  Preface to the 13^th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2026

  Anna Falanga, Benjamin Brenner, Alok A. Khorana

  16-04-2026

  https://doi.org/10.4081/btvb.2026.479

  149

  PDF: 95
• 

  PO60 | VEXAS SYNDROME AS A NEW SEVERE THROMBOPHILIC CLONAL CONDITION: A SINGLE CENTRE EXPERIENCE C. Ambaglio¹, E. Galimberti¹, F. Schieppati¹, M. Frigeni², M. Marchetti¹, L. Barcella¹, A. Falanga ^1|3 | ¹Immunohematology and Transfusion Medicine Unit, ASST Papa Giovanni XXIII, Bergamo; ²Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo; ³School of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.551

  127

  PDF: 28
• 

  PO23 | IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA RELATED TO DELAYED IMMUNE CHECKPOINT INHIBITORS TOXICITY: A CASE REPORT E. Galimberti¹, F. Schieppati¹, C. Ambaglio¹, M. Marchetti¹, L. Barcella¹, A. Falanga^1|2 | ¹Immunohematology and Transfusion Medicine Unit, ASST Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.518

  102

  PDF: 25
• 

  PO53 | PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF REGN7508^CAT FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I) J. Zwicker¹, M. P. O’Brien², M. Carrier³, J. Connors⁴, A. Falanga⁵, A. Manzano⁶, R. Mcbane⁷, Y.Y. Janjigian¹, G. O’Kane⁸, M. Onisko², J. Kaplan², A.P. Kithcart², D.E. Gutstein², A. Khorana⁹, M. F. Walsh² | ¹Memorial Sloan Kettering Cancer Center, New York, USA; ²Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; ³University of Ottawa, Ottawa, ON, Canada; ⁴Harvard Medical School, Boston, MA, USA; ⁵Hospital Papa Giovanni XXIII, Bergamo, Italy; ⁶Hospital Universitario 12 de Octubre, Madrid, Spain; ⁷Mayo Clinic, Rochester, MN, USA; ⁸St. Vincent's University Hospital and School of Medicine, University College Dublin, Dublin, Ireland; ⁹James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.545

  115

  PDF: 32
• 

  PO21 | PSYCHOLOGICAL IMPACT OF CANCER-ASSOCIATED THROMBOSIS: DUAL BURDEN AND IMPLICATIONS FOR QUALITY OF LIFE AND INTEGRATED PATIENT-CENTERED CARE G. Gerotziafas^1|4, Y. Mitrou⁵, M. Marchetti⁶, P. Las Casa¹, A. Tafur⁷, V. Bitsadze³, J. Khizroeva³, D. Taizhanova⁸, D. Antic⁹, C. Frére¹⁰, A. Makatsariya³, L. Garderet^1|11, A. Escargueil¹, C. Ay¹², N. Lomatkin¹³, Z. Tazi-Mezalek¹⁴, M. Sassi¹⁵, M. Catalano^4|16, J. Gligorov^1|17, J. Caprini¹⁸, P. Van Dreden^1|19, J. Fareed², A. Falanga⁶ | ¹Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP)Paris France; ²Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Chicago, USA; ³Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, The I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; ⁴VAS-European Independent Foundation in Angiology/Vascular Medicine Milan Italy; ⁵Department of Phylosophy, National and Kapodistrian University of Athens, Greece; ⁶Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy. School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; ⁷Vascular Medicine, Endeavor Health, Evanston, IL, USA; Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA; ⁸Department of Internal Diseases, Karaganda Medical University Non-Commercial Joint Stock Company, Karaganda, Kazakhstan; ⁹Clinic for Hematology, University Clinical Center of Serbia, Faculty of Medicine University of Belgrade Belgrade Serbia; ¹⁰Department of Hematology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, INSERM UMRS-1166 Institute of Cardiometabolism and Nutrition, Paris, France; ¹¹Clinical Haematology Department, Sorbonne Université, Pitié-Salpêtrière Hospital, APHP, Paris; ¹²Department of Internal Medicine I, Clinical Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria; ¹³Cardiology Division, Central Clinical Hospital of Presidential Administration, Moscow, Russia; ¹⁴Department of Internal Medicine, Hématologie Clinique, Centre Hospitalo-Universitaire Ibn Sina, Université Mohammed V de Rabat, Rabat, Morocco; ¹⁵Hematology Laboratory of Maternity and Neonatal Center of Monastir, Faculty of Pharmacy of Monastir, Monastir, Tunisia; ¹⁶Inter-University Research Center on Vascular Diseases, University of Milan-L Sacco Hospital, Milan, Italy; ¹⁷Medical Oncology Department, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University, Paris, France; ¹⁸Vascular Surgery, Pritzker School of Medicine at the University of Chicago, Chicago, USA; ¹⁹Clinical Research, Diagnostica Stago, Gennevilliers, France

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.516

  114

  PDF: 32
• 

  PO44 | PREDICTORS OF ONE-YEAR MORTALITY IN NEWLY DIAGNOSED METASTATIC BREAST CANCER: THE PROGNOSTIC ROLE OF HEMOSTATIC BIOMARKERS AND EARLY THROMBOEMBOLISM M. Marchetti^1|2|3, P. Gomez-Rosas^1|4|5, S. Bolognini¹, C. Ticozzi¹, D. Romeo¹, F. Schieppati^1|3, L. Barcella^1|3, F. Petrelli⁶, A. D'Alessio⁷, R. Labianca⁷, A. Falanga^1|2|3 | ¹Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; ³ERN EuroBloodNet; ⁴Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands; ⁵Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; ⁶Oncology Unit, Hospital Treviglio-Caravaggio, Treviglio, Italy; ⁷Fondazione ARTET Onlus, Bergamo, Italy; *On behalf of the Hypercan Investigators

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.538

  94

  PDF: 22
• 

  PO17 | PREDICTIVE VALUE OF INFLAMMATORY AND ENDOTHELIAL BIOMARKERS FOR CANCER RISK IN HEALTHY INDIVIDUALS: EVIDENCE FROM THE HYPERCAN STUDY C. Ticozzi¹, S. Bolognini^1|2, P. Gomez-Rosas^1|3, F. Schieppati^1|2, G. Sampietro⁴, L. Barcella¹, M. Marchetti^1|2, A. Falanga^1|2 | ¹Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; ³Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands; ⁴Unit of Epidemiology and Statistics, ATS Bergamo, Italy

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.512

  96

  PDF: 32
• 

  PO43 | ELEVATED CIRCULATING TISSUE PLASMINOGEN ACTIVATOR LEVELS PREDICT GASTROINTESTINAL AND BREAST CANCER RISK: A PROSPECTIVE NESTED CASE-COHORT STUDY S. Bolognini^1|2, C. Ticozzi¹, P. Gomez-Rosas^1|3, F. Schieppati^1|2, G. Sampietro⁴, L. Barcella¹, M. Marchetti^1|2, A. Falanga^1|2 | ¹Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; ³Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands; ⁴Unit of Epidemiology and Statistics, ATS Bergamo, Italy

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.537

  118

  PDF: 33
• 

  PO42 | DIFFERENTIAL EXPRESSION OF HEMOSTATIC BIOMARKERS ACROSS CANCER TYPE AND DISEASE STAGE: A PROSPECTIVE ANALYSIS OF 4,292 PATIENTS FROM THE HYPERCAN STUDY P. Gómez-Rosas^1|2|, D. Romeo¹, S. Bolognini¹, C. Ticozzi¹, F. Schieppati¹, A. D’Alessio⁴, R. Labianca⁴, A. Falanga^1|5|6, M. Marchetti^1|5|6 | ¹Hospital Papa Giovanni XXIII, Bergamo, Italy; ²Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands; ³Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; ⁴Fondazione ARTET Onlus, Bergamo, Italy; ⁵ERN EuroBloodNet; ⁶School of Medicine and Surgery, University of Milan Bicocca, Italy; *On Behalf Of The Hypercan Investigators

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.536

  100

  PDF: 26
• 

  PO27 | URINE QUALITATIVE ASSESSMENT OF DIRECT ORAL ANTICOAGULANTS IN ROUTINE CLINICAL PRACTICE F. Schieppati^1|2, P. Gomez-Rosas^1|3, C. Ambaglio¹, V. Brusegan¹, O.C. Cretu¹, E. Galimberti¹, F. Zunino¹, L. Barcella¹, J. Harenberg^4|5, A. Falanga^1|2, M. Marchetti^1|2 | ¹Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; ³Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; ⁴Ruprecht Karls University of Heidelberg, Heidelberg, Germany; ⁵DOASENSE GmbH, Heidelberg, Germany

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.522

  97

  PDF: 32
• 

  PO25 | EVOLUTION OF ANTICOAGULANT STRATEGIES AND CLINICAL OUTCOMES IN CANCER-ASSOCIATED THROMBOSIS: A LONGITUDINAL ANALYSIS OF THE START2 REGISTRY ONCO-VTE M. Marchetti^1|2, T. Zollner^1|2, OC. Cretu^1|2, A. Chistolini³, R. Pancani⁴, L. Puccetti⁵, P. Sivera⁶, W. Ageno⁷, G. Elmi⁸, V. Fregoni⁹, V. Tonelli¹⁰, E. Antonucci¹¹, D. Poli^11|12, A. Falanga^1|2, L. Barcella^1|2 | ¹Hemostasis & Thrombosis Center, Department of Transfusion Medicine, Papa Giovanni XXIII Hospital, Bergamo Italy; ²ERN EuroBloodNet; ³Hematology Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; ⁴Pulmonary Unit, Hospital of Siena, University of Siena, Siena, Italy; ⁵Hemostasis and Thrombosis Unit, Hospital of Siena, University of Siena, Siena, Italy; ⁶Haematology Unit, Ordine Mauriziano Hospital, Turin, Italy; ⁷Department of Medicine, University of Padua, Padua, Italy; ⁸Department of Medicine, Maggiore Hospital, Bologna, Italy; ⁹Department of Medicine, Sondalo Hospital, Sondalo, Italy; ¹⁰Angiology Unit, Sant'Eugenio Hospital, Rome, Italy; ¹¹Arianna Anticoagulazione Foundation, Bologna, Italy; ¹²Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.520

  114

  PDF: 29